Your session is about to expire
← Back to Search
Behavioural Intervention
reSET-O for Opioid Use Disorder
N/A
Waitlist Available
Research Sponsored by Pear Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Provide written informed consent prior to any study specific assessments being performed
Male or female ≥18 years of age, inclusive
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from week 1 to week 4
Awards & highlights
Study Summary
This trial will test a new digital therapy to help people start and stick with buprenorphine treatment for opioid addiction.
Eligible Conditions
- Opioid Use Disorder
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You are able to use common software applications on an internet-enabled mobile device (smart phone or tablet).
Select...
You are interested in testing or using PEAR-002b.
Select...
You have no prior history of use of reSET-O.
Select...
You have not participated in any other investigational drug trials within the past 30 days (or within 5 half-lives of study drug, whichever is longer) of enrollment.
Select...
You are able to understand and communicate in English.
Select...
You are currently using buprenorphine.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from week 1 to week 4
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from week 1 to week 4
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Buprenorphine Initiation Success
Medication Adherence Rates
PEAR-002B Qualitative User Experience Interviews
+1 moreSecondary outcome measures
PEAR-002B Engagement Data
reSET-O Qualitative User Experience Interviews
reSET-O User Satisfaction Surveys
Other outcome measures
Abstinence From Illicit Opioids
Device Wearing Time
Physiological Biomarker Data
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: PEAR-002B / reSET-OExperimental Treatment2 Interventions
Digital Therapeutic
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PEAR-002B
2022
N/A
~10
reSET-O
2022
N/A
~60
Find a Location
Who is running the clinical trial?
Whitman-Walker Institute, Inc.OTHER_GOV
Hassman Research Institute, LLCUNKNOWN
Pear Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
1,910 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
Oregon
How old are they?
18 - 65
What site did they apply to?
Whitman-Walker, Inc
What portion of applicants met pre-screening criteria?
Met criteria
How responsive is this trial?
Typically responds via
Email
Share this study with friends
Copy Link
Messenger